Similar Search Results

The political economy of early Covid-19 interventions in US states

Gonzalez-Eiras, Martín; Niepelt, Dirk - 2022

We investigate how politico-economic factors shaped government responses to the spread of COVID-19. Our simple framework uses epidemiological, economic and politico-economic arguments. Confronting the theory with US state level data we find strong evidence for partisanship even when we control...

Persistent link: https://www.econbiz.de/10012801483

The contribution of pharmaceutical innovation to longevity growth in Germany and France

Lichtenberg, Frank R. - 2010

-adjusted mortality rates of residents of Germany, using longitudinal, annual, state-level data during the period 2000-2007. The estimates …-adjusted cancer mortality rates of residents of France, using longitudinal, annual, cancer-site-level data during the period 2002 … mortality rates, and may have accounted for as much as half of the decline. …

Persistent link: https://www.econbiz.de/10003977959

Optimally controlling an epidemic

Gonzalez-Eiras, Martín; Niepelt, Dirk - 2020

We propose a flexible model of infectious dynamics with a single endogenous state variable and economic choices. We characterize equilibrium, optimal outcomes, static and dynamic externalities, and prove the following: (i) A lockdown generically is followed by policies to stimulate activity....

Persistent link: https://www.econbiz.de/10012388160

On the optimal "lockdown" during an epidemic

Gonzalez-Eiras, Martín; Niepelt, Dirk - 2020

We embed a lockdown choice in a simplified epidemiological model and derive formulas for the optimal lockdown intensity and duration. The optimal policy reflects the rate of time preference, epidemiological factors, the hazard rate of vaccine discovery, learning effects in the health care...

Persistent link: https://www.econbiz.de/10012206448

Tractable epidemiological models for economic analysis

Gonzalez-Eiras, Martín; Niepelt, Dirk - 2020

We contrast the canonical epidemiological SIR model due to Kermack and McKendrick (1927) with more tractable alternatives that offer similar degrees of "realism" and exibility. We provide results connecting the different models which can be exploited for calibration purposes. We use the expected...

Persistent link: https://www.econbiz.de/10012226626

On the optimal "lockdown" during an epidemic

Gonzalez-Eiras, Martín; Niepelt, Dirk - In: Covid economics : vetted and real-time papers (2020) 7, pp. 68-87

Persistent link: https://www.econbiz.de/10012215969

Response to Baker and Fugh-Berman's critique of my paper, "Why has longevity increased more in some states than in others?"

Lichtenberg, Frank R. - 2009

study was subject to a number of major methodological flaws. Many of their claims pertain to the role of infant mortality …. I show that infant mortality was not an important determinant of the growth in U.S. life expectancy during the period … that I studied, and that my estimates are completely insensitive to the inclusion or exclusion of infant mortality …

Persistent link: https://www.econbiz.de/10003861794

The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010 : evidence from longitudinal, disease-level data

Lichtenberg, Frank R.; Pettersson, Billie - 2012

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...

Persistent link: https://www.econbiz.de/10009571756

Sources of US longevity increase, 1960 - 1997

Lichtenberg, Frank R. - 2000

Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% G from 69.7 to 76.5 years G and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. While life expectancy has tended to increase, there...

Persistent link: https://www.econbiz.de/10011397757

The impact of recent chemotherapy innovation on the longevity of Myeloma patients : U.S. and international evidence

Lichtenberg, Frank R.; Hostenkamp, Gisela - 2013

myeloma mortality rate using longitudinal country-level data on 26 countries during the period 2005-2009. Countries that had … larger increases in the number of chemotherapy regimens had larger subsequent declines in myeloma mortality rates …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

Persistent link: https://www.econbiz.de/10010223067